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PURPOSE. To determine risk factors associated with structural progression in medically
treated normal-tension glaucoma (NTG).
METHODS. This retrospective cohort study included 166 NTG patients (average age, 56.5
years; average mean deviation, −4.2 dB). The structural progression endpoint was deter-
mined by optical coherence tomography; significant thickness differences in the peri-
papillary retinal nerve fiber layer (RNFL) or macular ganglion cell inner plexiform layer
(GCIPL) that exceeded baseline test-retest variability were identified with event-based
guided-progression analysis. Intraocular pressure and systemic blood pressure (BP) were
measured at each visit throughout the follow-up period, and the risk for progression was
evaluated with Cox regression. Myopic disc features and antihypertensives were also
analyzed. Tree analysis was used to determine the cutoff values and elucidate influential
risk factors.
RESULTS. Structural progression, defined as progressive peripapillary RNFL or macular
GCIPL thinning, was identified in 62 eyes. Occurrence of disc hemorrhages, presence
of diabetes, and lower minimum systolic BP were associated with progression (hazard
ratio [HR]: 2.116, P = 0.005; HR: 1.998, P = 0.031; HR: 0.968, P = 0.005; respectively).
The cutoff value derived from the tree analysis of minimum systolic BP was 108 mm Hg.
The tree analysis revealed systolic and diastolic BP to be the most influential risk factors
for progressive peripapillary RFNL thinning and progressive macular GCIPL thinning,
respectively.
CONCLUSIONS. Low BP measured during follow-up correlated with structural progression
in medically treated NTG eyes, indicating that the evaluation of hypotension is required
during the management of NTG patients. The tree analysis identified BP target values
that may help prevent glaucoma progression.
Keywords: ganglion cell inner plexiform layer, normal-tension glaucoma, optical coher-
ence tomography, glaucoma progression, retinal nerve fiber layer
Normal-tension glaucoma (NTG) is a type of progres-sive glaucomatous optic neuropathy associated with a
normal range of intraocular pressure (IOP).1 Although IOP
is considered to be the most significant risk factor for NTG
progression, several others, including aberrant systemic and
ocular hemodynamics, have also been reported to influence
the development and progression of NTG.2–4 The effect of
myopia on NTG progression, however, remains controver-
sial.5,6
Although standard automated perimetry (SAP) is most
commonly used as a periodic visual field (VF) exami-
nation to monitor the progression of glaucoma, SAP is
limited by its subjectivity and its sensitivity to short- or
long-term fluctuations in results7; by contrast, the use of
optical coherence tomography (OCT) to perform a struc-
tural progression analysis benefits from superior objectiv-
ity and ease of interpretation. Hence, temporal changes
in the retinal nerve fiber layer (RNFL) or ganglion cell-
inner plexiform layer (GCIPL) thickness measured with OCT
feature widespread application as indices of the structural
progression of glaucoma.8,9 In addition, structural progres-
sion detected by OCT can reportedly predict VF progression
with better repeatability and reproducibility than can the
VF test.10
This study aimed to evaluate the effect of IOP, myopic
disc change, and systemic blood pressure (BP) on the struc-
tural progression of NTG. Decision tree analysis was used to
determine the cutoff value and significance of each param-
eter. This study also examined the association between
antihypertensive medication and structural progression. We
expect these analyses to yield target values that will help to
prevent glaucoma progression.
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METHODS
This study was approved (4-2019-0835) by the Institu-
tional Review Board of Severance Hospital, Yonsei Univer-
sity College of Medicine and adhered to the Declaration of
Helsinki. We retrospectively reviewed the medical records
of all the patients who visited the glaucoma clinic at our
institution from November 2012 to July 2019. The require-
ment for informed consent was waived owing to our study’s
retrospective design and anonymization of clinical data.
All participants underwent complete ophthalmic exam-
inations: the measurements of best-corrected visual acuity,
IOP with a Goldmann applanation tonometer, and central
corneal thickness; slit-lamp biomicroscopy; dilated fundus
examination; color disc photography (Carl Zeiss Meditec,
Jena, Germany); spectral-domain OCT (Cirrus HD-OCT, soft-
ware v11.0, Carl Zeiss Meditec); axial-length (AL) measure-
ment (IOL Master, Carl Zeiss Meditec); and a VF test
(Humphrey Field Analyzer II; Carl Zeiss Meditec). Patients
were followed up every six months for at least two years,
and OCT examinations were performed once or twice a
year. IOP and BP (right arm, sitting) were measured at each
visit. Based on standard clinical protocol, all subjects were
seated in a quiet location for at least five minutes before the
measurements.
The mean IOP was calculated by averaging all the
measurements during the follow-up period. If patients
underwent cataract surgery, all postoperative IOP measure-
ments obtained during the six weeks after the surgery were
excluded to avoid the inclusion of transient IOP changes.
The standard deviation (SD) of IOP measurements was used
to define IOP fluctuation (SD IOP). Peak IOP was the single
highest measurement recorded during the entire follow-up.
Mean systolic BP (SBP) and diastolic BP (DBP) were calcu-
lated by averaging all the corresponding BP measurements.
SBP and DBP fluctuations were defined using the SD of BP
measurements. Maximum and minimum SBP or DBP were
the highest and lowest corresponding single measurements
during the entire follow-up, respectively. Mean arterial pres-
sure (MAP) was calculated as 1/3 mean SBP + 2/3 mean
DBP.Mean ocular perfusion pressure (MOPP) was calculated
as 2/3 MAP − mean IOP. Systolic perfusion pressure (SPP)
was calculated as the mean SBP − mean IOP, and diastolic
perfusion pressure (DPP) was calculated as the mean DBP −
mean IOP. When structural progression was detected, only
IOP and BP measurements obtained before the detection
were included in subsequent analyses.
Data on antihypertensive-medication use were obtained
when available from electronic health records. Antihyper-
tensive medications were categorized into four classes:
diuretics, β-blockers, calcium channel blockers (CCBs), and
angiotensin II receptor blockers.
The inclusion criteria included a best-corrected visual
acuity of 20/40 or better and an open angle on gonioscopy.
NTG was diagnosed when the maximum untreated IOP was
< 21 mm Hg on three repeated measurements obtained at
different times on separate follow-up visits and in the pres-
ence of glaucomatous optic discs (neuroretinal rim thinning
and excavation) and peripapillary RNFL defect—regardless
of the presence or absence of glaucomatous VF defects. Indi-
viduals with the following were excluded: (1) secondary
causes of glaucomatous optic neuropathy, (2) history of glau-
coma (including glaucoma filtration surgery) or refractive
surgery, and (3) neurologic or systemic diseases influencing
OCT measurements. Because our preliminary data showed
a potential floor effect for RNFL and GCIPL (Supplementary
Fig. S1), we also excluded eyes with a mean deviation (MD)
< −20 dB and RNFL and GCIPL thicknesses < 65 μm. If both
eyes were eligible for inclusion, one of the participant’s eyes
was randomly selected.
Measurement of Parameters Related to Optic-Disc
Tilt and Torsion
Color fundus images were evaluated by two investigators
(H.Y. and K.L.) in a masked fashion using ImageJ software
(v1.52; National Institutes of Health, Bethesda, MD, USA).
The disc-tilt ratio was defined as the ratio between the
longest and shortest diameters of the optic disc. Optic-disc
torsion was defined as the deviation angle of the long axis
of the optic disc from the vertical meridian: the vertical line
situated 90° from the line that connects the fovea and the
center of the optic disc.11 The average measurements of the
two investigators were used in the final analysis.
Optical Coherence Tomography
The OCT images of the peripapillary RNFL and macular
GCIPL were obtained with optic disc cube and macular
scans, respectively, using a Cirrus HD-OCT. The optic disc
cube scan produced an RNFL thickness map of 6 × 6 mm
(200 × 200 pixels) in area centered on the optic nerve head.
The peripapillary RNFL thickness was measured circularly
with a diameter of 3.46 mm. The macular cube scan gener-
ated a GCIPL thickness map of 6 × 6 mm (512 × 128 pixels)
in area centered on the fovea. The macular GCIPL thickness
was measured in the annulus with inner vertical and hori-
zontal diameters of 1 and 1.2 mm, respectively, and outer
vertical and horizontal diameters of 4 and 4.8 mm, respec-
tively. At least five reliable OCT scans from separate visits
were required for study inclusion. All OCT scans had a signal
strength of ≥6. Scans with motion artefacts, poor centration,
or missing data were excluded.
Guided Progression Analysis of the Ganglion
Cell-Inner Plexiform Layer and Retinal Nerve
Fiber Layer
We evaluated the structural progression of peripapillary
RNFL and macular GCIPL using an event-based algorithm
provided by guided progression analysis (GPA). The GPA
algorithm compared the changes in peripapillary RNFL
and macular GCIPL thicknesses at individual superpixels
(1 superpixel = 4 × 4 pixels) between the follow-up and
two baseline thickness maps. For the change to be classified
as significant, a change of at least 20 adjacent superpixels
must be detected in the RNFL or GCIPL thickness maps. If
a follow-up OCT examination demonstrated a statistically
significant difference in thickness that exceeded the base-
line test-retest variability, the superpixel was labeled yellow
to indicate possible loss; if confirmed on a second follow-
up OCT examination, it was labeled red to signal probable
loss. Progressive thinning of peripapillary RNFL and macu-
lar GCIPL was defined as a “likely loss” in the event analysis
during follow-up, with the same changes being observed in
the most recent follow-up visit.
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Perimetry
SAP was performed using the Swedish interactive thresh-
old algorithm standard 24-2 program in the Humphrey Field
Analyzer II. Only reliable VF test results (false-positive errors
< 15%, false-negative errors < 15%, and fixation loss < 20%)
were included.
Decision Tree Analysis
The decision tree analysis model is a statistical tool used to
separate a group into two subgroups based on individual
risk factors. The decision tree analysis was performed using
the ctree function in the party package of R, which enables
conditional inference tree analysis.12 Briefly, conditional
inference tree analysis generates a decision tree by recur-
sively partitioning the population of interest into subgroups.
At each partition, it searches for the best predictor and
corresponding cutoff value that splits one group into two
subgroups such that the response is significantly differ-
ent between the two groups. Because multiple predictors
are considered, Bonferroni correction is used to counteract
multiple comparisons.13 Traditional decision tree analysis,
such as classification and regression trees, selects variables
that maximize information measurement (Gini coefficient or
information gain). This method can produce complex trees,
called overfits, that are not generated well from training data.
Therefore some techniques such as pruning are needed to
avoid this problem. However, the conditional inference tree
analysis used in this study benefits from not requiring such a
technique, because this method uses statistical theory (selec-
tion by permutation-based significance testing) and thereby
removes the potential bias in classification and regression
trees or similar decision trees.13 Factors that were found to
be associated with structural progression in the univariable
Cox analysis were used as the input variables.
Statistical Analysis
Statistical analysis was performed using the R software
v3.6.0 (R Foundation for Statistical Computing, Vienna,
Austria). Baseline clinical variables are presented as mean ±
SD. Structural progression was categorized into at least one
of three groups: progressive peripapillary RNFL or macu-
lar GCIPL thinning, progressive peripapillary RNFL thinning,
progressive macular GCIPL thinning. Univariable and multi-
variable Cox regression was used to calculate the hazard
ratios (HRs) of clinical variables for each structural progres-
sion. HR was described as a mean with a 95% confidence
interval. To avoid multicollinearity complications, we calcu-
lated the variance inflation factor and excluded variables
with values of above 2.5. Because DBP and SBP corre-
lated with each other, we excluded one variable with the
Akaike information criterion calculation when both vari-
ables were included in the multivariate analysis. Student’s
t-test was used to compare the clinical variables between
two groups according to history of hypertension (HTN)
or antihypertensive medication use. Decision tree analysis
was performed as described above. Kaplan-Meier analysis
was used to compare the progression rate between groups
defined by the decision tree analysis. We also used Cox
regression to calculate the HRs of the groups defined by the
tree analysis. All tests reported P values as bilateral; those
of less than 0.05 were considered statistically significant.
RESULTS
We identified 213 eyes of 213 NTG patients and selected
166 eyes based on inclusion and exclusion criteria. The base-
line means of age, AL, and IOP were 56.3 ± 15.3 years, 24.3
± 1.7 mm, and 14.9 ± 2.4 mm Hg, respectively. Clinical vari-
ables including baseline peripapillary RNFL thickness, macu-
lar GCIPL thickness, and MD are described in Table 1. The
mean follow-up period was 48.9 ± 15.2 months. Structural
progression was identified in 62 eyes: 21, only progressive
peripapillary RNFL thinning; 18, only progressive macular
GCIPL thinning; 23, both peripapillary RNFL and macular
GCIPL thinning.
Identification of Factors Associated with
Structural Progression
The univariable Cox regression analysis identified diabetes,
disc hemorrhage, SD IOP, mean SBP, minimum SBP, mean
DBP, minimum DBP, MAP, MOPP, SPP, and DPP as being
associated with structural progression when defined as
progressive peripapillary RNFL or macular GCIPL thinning
(Table 2). The multivariable Cox regression analysis revealed
diabetes, disc hemorrhage, and minimum SBP to be associ-
ated with structural progression (Table 2). SD IOP was asso-
ciated with structural progression after having adjusted for
diabetes and disc hemorrhage (HR = 1.784 [1.031–3.084],
P = 0.038).
Disc hemorrhage, SD IOP, mean SBP, minimum SBP, mini-
mum DBP, and SPP were associated with structural progres-
sion when defined as progressive peripapillary RNFL thin-
ning in univariable Cox regression analysis; disc hemorrhage
and minimum SBP remained associated with progressive
peripapillary RNFL thinning in the multivariable Cox regres-
sion analysis (Table 3).
Disc hemorrhage, mean SBP, minimum SBP, mean DBP,
minimum DBP, maximum DBP, MAP, MOPP, SPP, and DPP
were associated with structural progression when defined as
progressive macular GCIPL thinning in the univariable Cox
regression analysis; disc hemorrhage and minimum DBP
remained associated with progressive macular GCIPL thin-
ning in the multivariable Cox regression analysis (Table 4).
Effect of Antihypertensives on Structural
Progression
Subgroup analysis of patients with HTN was performed
to evaluate the effect of antihypertensives on structural
progression. Compared to participants without HTN, those
with HTN were older (P < 0.001) and had a more exten-
sive history of diabetes (P < 0.001) and shorter axial length
(P = 0.002, Supplementary Table S1). Data on antihyperten-
sive medication prescriptions were available for 34 patients.
Twenty-two patients used angiotensin II receptor blockers;
18, CCB; 11, β-blockers; and six, diuretics. Eighteen patients
used only one type of drug, whereas 16 patients used two
or more. The univariable Cox regression analysis revealed a
significant association between CCB prescription and struc-
tural progression when defined as progressive peripapil-
lary RNFL or macular GCIPL thinning (HR = 0.201 [0.052–
0.773], P = 0.020, Supplemental Table S2). However, this
effect did not remain significant after adjusting for mean SBP
(P = 0.118, Supplemental Table S2). The results for peripap-
illary RNFL and macular GCIPL thinning are presented in
Supplemental Tables S3 and S4.
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(n = 62) P *
Age, years 56.3 ± 15.3 57.3 ± 14.2 54.8 ± 16.9 0.309
Hypertension, n (%) 54 (32.5%) 30 (28.8%) 24 (38.7%) 0.254
Diabetes mellitus, n (%) 24 (14.5%) 11 (10.6%) 13 (21.0%) 0.107
Central corneal thickness (μm) 536.0 ± 37.0 538.2 ± 32.5 532.2 ± 44.0 0.394
Disc hemorrhage, n (%) 44 (26.5%) 19 (18.3%) 25 (40.3%) 0.003
RNFL thickness, μm 80.8 ± 8.9 79.9 ± 8.6 82.4 ± 9.3 0.085
GCIPL thickness, μm 74.5 ± 5.7 74.5 ± 5.9 74.6 ± 5.5 0.914
Mean deviation, dB −4.2 ± 3.8 −4.1 ± 3.3 −4.5 ± 4.6 0.507
Axial length, mm 24.3 ± 1.7 24.1 ± 1.5 24.6 ± 1.8 0.252
Disc torsion, degrees 0.5 ± 8.0 0.7 ± 7.4 0.3 ± 8.9 0.806
Disc tilt ratio 1.2 ± 0.2 1.1 ± 0.2 1.2 ± 0.2 0.078
Baseline IOP, mm Hg 14.9 ± 2.4 14.8 ± 2.3 15.0 ± 2.7 0.624
Mean IOP, mm Hg 13.0 ± 1.8 13.0 ± 1.9 13.0 ± 1.7 0.988
SD IOP, mm Hg 1.6 ± 0.5 1.5 ± 0.4 1.7 ± 0.5 0.034
Peak IOP, mm Hg 15.6 ± 2.2 15.4 ± 2.2 15.9 ± 2.1 0.117
Mean SBP, mm Hg 121.8 ± 12.4 123.2 ± 12.8 119.4 ± 11.5 0.054
Minimum SBP, mm Hg 109.0 ± 13.4 110.5 ± 13.8 106.4 ± 12.4 0.055
Maximum SBP, mm Hg 134.8 ± 14.2 135.9 ± 14.3 133.1 ± 13.9 0.229
SD SBP, mm Hg 10.1 ± 4.6 10.2 ± 4.9 10.0 ± 4.1 0.727
Mean DBP, mm Hg 71.1 ± 8.3 71.8 ± 8.6 69.9 ± 7.8 0.148
Maximum DBP, mm Hg 80.7 ± 9.7 81.4 ± 9.5 79.7 ± 10.0 0.274
Minimum DBP, mm Hg 61.8 ± 9.4 62.8 ± 9.9 60.1 ± 8.5 0.084
SD DBP, mm Hg 7.4 ± 3.0 7.4 ± 3.0 7.4 ± 3.0 0.973
MAP, mm Hg 88.0 ± 9.3 88.9 ± 9.5 86.4 ± 8.6 0.085
MOPP, mm Hg 50.0 ± 6.1 50.6 ± 6.2 48.9 ± 6.0 0.082
SPP, mm Hg 108.7 ± 12.4 110.2 ± 12.5 106.3 ± 11.9 0.054
DPP, mm Hg 58.0 ± 8.2 58.8 ± 8.3 56.8 ± 8.0 0.143
Parameters are presented as the mean ± standard deviation or n (%).
* P values were calculated with t-tests. Indicated in bold type, P < 0.05 indicates statistical significance.
TABLE 2. Univariable and Multivariable Cox Analysis of Progressive Peripapillary RNFL or Macular GCIPL Thinning
Univariable Cox Analysis Multivariable Cox Analysis
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Age, years 1.001 0.984–1.018 0.921
Hypertension 1.612 0.960–2.707 0.071
Diabetes mellitus 1.971 1.062–3.656 0.031 1.998 1.067–3.742 0.031
Central corneal thickness (μm) 0.999 0.9991–1.006 0.736
Disc hemorrhage 2.191 1.309–3.667 0.003 2.116 1.260–3.555 0.005
RNFL thickness, μm 1.013 0.986–1.040 0.353
GCIPL thickness, μm 0.987 0.943–1.034 0.584
Mean deviation, dB 0.977 0.915–1.044 0.500
Axial length, mm 0.967 0.780–1.198 0.758
Disc torsion, degrees 0.982 0.950–1.015 0.279
Disc tilt ratio 1.250 0.485–3.222 0.644
Baseline IOP, mm Hg 0.968 0.865–1.083 0.566
Mean IOP, mm Hg 0.982 0.843–1.145 0.820
SD IOP, mm Hg 1.798 1.034–3.127 0.038 1.417 0.794–2.532 0.239
Peak IOP, mm Hg 1.028 0.911–1.160 0.656
Mean SBP, mm Hg 0.965 0.943–0.987 0.002
Minimum SBP, mm Hg 0.963 0.942–0.984 0.001 0.968 0.947–0.990 0.005
Maximum SBP, mm Hg 0.984 0.965–1.004 0.119
SD SBP, mm Hg 1.011 0.955–1.071 0.709
Mean DBP, mm Hg 0.956 0.924–0.990 0.012
Maximum DBP, mm Hg 0.979 0.951–1.007 0.132
Minimum DBP, mm Hg 0.967 0.943–0.991 0.007
SD DBP, mm Hg 1.009 0.931–1.094 0.826
MAP, mm Hg 0.954 0.925–0.985 0.004
MOPP, mm Hg 0.934 0.891–0.980 0.005
SPP, mm Hg 0.966 0.945–0.988 0.003
DPP, mm Hg 0.957 0.924–0.991 0.014
Indicated in bold type, P < 0.05 indicates statistical significance. CI, confidence interval.
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TABLE 3. Univariable and Multivariable Cox Analysis of Progressive Peripapillary RNFL Thinning
Univariable Cox Analysis Multivariable Cox Analysis
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Age, years 0.984 0.965–1.003 0.100
Hypertension 1.050 0.560– 1.968 0.879
Diabetes mellitus 1.410 0.669–2.972 0.367
Central corneal thickness (μm) 1.004 0.995–1.014 0.337
Disc hemorrhage 2.535 1.387–4.631 0.002 2.523 1.367–4.655 0.003
RNFL thickness, μm 1.032 0.999–1.065 0.054
GCIPL thickness, μm 0.969 0.914–1.026 0.282
Mean deviation, dB 1.058 0.971–1.152 0.198
Axial length, mm 1.114 0.887–1.399 0.355
Disc torsion, degrees 0.990 0.952–1.030 0.634
Disc tilt ratio 1.451 0.540–3.897 0.460
Baseline IOP, mm Hg 1.057 0.935–1.196 0.376
Mean IOP, mm Hg 0.994 0.802–1.136 0.599
SD IOP, mm Hg 2.253 1.159–4.379 0.017 1.473 0.733–2.962 0.277
Peak IOP, mm Hg 1.013 0.880–1.166 0.857
Mean SBP, mm Hg 0.967 0.941–0.994 0.016
Minimum SBP, mm Hg 0.954 0.929–0.979 <0.001 0.956 0.930–0.983 0.002
Maximum SBP, mm Hg 0.990 0.967–1.013 0.383
SD SBP, mm Hg 1.044 0.979–1.112 0.189
Mean DBP, mm Hg 0.973 0.935–1.013 0.177
Maximum DBP, mm Hg 0.963 0.934–0.993 0.017
Minimum DBP, mm Hg 0.997 0.968–1.028 0.865
SD DBP, mm Hg 1.073 0.976–1.180 0.146
MAP, mm Hg 0.965 0.930–1.001 0.057
MOPP, mm Hg 0.953 0.902–1.006 0.080
SPP, mm Hg 0.970 0.944–0.996 0.022
DPP, mm Hg 0.976 0.938–1.015 0.229
Indicated in bold type, P < 0.05 indicates statistical significance. CI, confidence interval.
TABLE 4. Univariable and Multivariable Cox Analysis of Progressive Macular GCIPL Thinning
Univariable Cox Analysis Multivariable Cox Analysis
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Age, years 1.007 0.986–1.028 0.522
Hypertension 1.664 0.882–3.140 0.116
Diabetes mellitus 1.500 0.689–3.264 0.307
Central corneal thickness (μm) 0.996 0.988–1.004 0.356
Disc hemorrhage 2.244 1.183–4.256 0.013 1.983 1.037–3.790 0.038
RNFL thickness, μm 1.009 0.975–1.044 0.611
GCIPL thickness, μm 0.997 0.944–1.053 0.924
Mean deviation, dB 0.934 0.870–1.003 0.062
Axial length, mm 0.938 0.717–1.226 0.639
Disc torsion, degrees 0.994 0.955–1.034 0.752
Disc tilt ratio 1.611 0.546–4.753 0.387
Baseline IOP, mm Hg 0.963 0.838–1.106 0.594
Mean IOP, mm Hg 1.008 0.837–1.214 0.935
SD IOP, mm Hg 1.689 0.860–3.319 0.128
Peak IOP, mm Hg 1.020 0.876–1.186 0.801
Mean SBP, mm Hg 0.965 0.939–0.993 0.014
Minimum SBP, mm Hg 0.969 0.944–0.994 0.016
Maximum SBP, mm Hg 0.982 0.959–1.006 0.134
SD SBP, mm Hg 0.986 0.917–1.061 0.708
Mean DBP, mm Hg 0.940 0.899–0.982 0.005
Maximum DBP, mm Hg 0.961 0.933–0.990 0.008
Minimum DBP, mm Hg 0.964 0.930–0.999 0.042 0.965 0.936–0.995 0.022
SD DBP, mm Hg 0.984 0.888–1.089 0.750
MAP, mm Hg 0.946 0.909–0.984 0.005
MOPP, mm Hg 0.920 0.868–0.976 0.006
SPP, mm Hg 0.966 0.940–0.993 0.015
DPP, mm Hg 0.938 0.897–0.981 0.005
Indicated in bold type, P < 0.05 indicates statistical significance. CI, confidence interval.
Risk Factors for Structural Change of Glaucoma IOVS | July 2020 | Vol. 61 | No. 8 | Article 35 | 6
FIGURE 1. (A) Decision tree analysis for structural progression when defined as progressive peripapillary retinal nerve fiber layer or macular
ganglion cell-inner plexiform layer thinning; (B) Kaplan-Meier analysis showing significant differences in the progression rate between the
two groups defined by the tree analysis. MinSBP, minimum systolic blood pressure.
FIGURE 2. (A) Decision tree analysis for progressive peripapillary retinal nerve fiber layer thinning; (B) Kaplan-Meier analysis showing
significant differences in the progression rate between the three groups defined by the tree analysis. MinSBP, minimum systolic blood
pressure; DH, disc hemorrhage.
Decision Tree Analysis
The clinical variables that were found to be significantly
associated with structural progression in the univariable Cox
regression analysis were used as possible risk factors in
the decision tree analysis. When structural progression was
defined as progressive peripapillary RNFL of macular GCIPL
thinning, minimum SBP was the most important factor, with
a cutoff value of 108 mm Hg (Fig. 1A). Kaplan-Meier analysis
also showed statistically different rates of structural progres-
sion (Fig. 1B). Eyes with a minimum SBP ≤ 108 mm Hg
showed more progression than did eyes with a minimum
SBP < 108 mm Hg (HR 2.563 [1.494–4.396], P < 0.001).
In terms of progressive peripapillary RNFL thinning,mini-
mum SBP and disc hemorrhage were found to be the most
significant factors (Fig. 2A). A minimum SBP > 107 mm
Hg was associated with the least progression of peripapil-
lary RNFL thinning. For the minimum SBP of ≤ 107 mmHg,
disc hemorrhage was significantly associated with progres-
sive peripapillary RNFL thinning. Kaplan-Meier analysis also
showed statistically different rates of structural progression
(Fig. 2B). Compared to a minimum SBP > 107 mm Hg, the
HR of eyes without disc hemorrhage and a minimum SBP ≤
107 mm Hg was 3.165 (1.435–6.981; P = 0.004), and that of
eyes with disc hemorrhage and a minimum SBP ≤ 107 mm
Hg was 7.602 (3.391–17.044; P < 0.001).
Minimum DBP was the most significant factor associated
with progressive macular GCIPL thinning (Fig. 3A). Kaplan-
Meier analysis revealed a difference in the rate of progres-
sive macular GCIPL thinning between eyes with a minimum
DBP > 63 mm Hg and those with ≤63 mm Hg (Fig. 3B). In
contrast with eyes with a minimum DBP > 63 mm Hg (P <
0.001), the HR of eyes with a minimum DBP ≤ 63 mm Hg
was 5.889 (2.297–15.096).
DISCUSSION
This study used tree analysis to identify and elucidate
the significance of risk factors associated with the struc-
tural progression of NTG. Diabetes, disc hemorrhage, and
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FIGURE 3. (A) Decision tree analysis for progressive macular GCIPL thinning; (B) Kaplan-Meier analysis showing significant differences in
the progression rate between the two groups defined by the tree analysis. MinDBP, minimum diastolic blood pressure.
minimum SBP were found to significantly influence struc-
tural progression. The tree analysis identified 108 mm Hg as
the cutoff value for minimum SBP and revealed minimum
SBP and DBP to be the most significant variables for progres-
sive peripapillary RNFL thinning and progressive macular
GCIPL thinning, respectively. Although CCB demonstrated
a preventive effect in the eyes of patients with HTN, this
effect was found to be nonsignificant after adjusting for BP
parameters.
Previous studies have found an association between
the incidence of glaucoma and low BP.14,15 Consistent
with the present findings, Kaiser et al.2 showed that func-
tional progression can occur in patients with low BP in
patients with POAG and NTG, despite their IOP being well
controlled. We have proposed cutoff (target) values for mini-
mum SBP and DBP: 107–108 mm Hg and 63 mm Hg, respec-
tively. Leske et al. 14 observed low SPP, DPP, and SBP to
be associated with the incidence of glaucoma (relative risk
ratios (RR): 0.91, 0.87, and 0.79 per 10 mm Hg, respectively).
Individuals with an SPP < 98 mm Hg had a higher risk of
glaucoma progression than those with an SPP > 153 mm
Hg (RR, 2.0), and a DPP < 53 mm Hg was associated with
a higher risk of glaucoma progression than was a DPP >
73 mm Hg (RR 2.1).14 Tham et al.15 found that, relative to
individuals with an SBP of between 138 and 153 mm Hg,
the odds ratio of those with an SBP < 124 mm Hg was
1.69 for primary open-angle glaucoma (POAG). Therefore
the present investigation differs from previous studies in
two ways: (1) our cutoff values for BP control were eluci-
dated with decision tree analysis, and (2) we analyzed risk
factors for the progression of glaucoma—not its incidence.
Our findings indicate that hypotension is closely related to
not only the development of glaucoma but also to its struc-
tural progression.
SBP and DBP seem to have greater effects on other struc-
tures of the eye. According to the tree analysis, minimum
SBP featured a stronger association with progressive peri-
papillary RNFL thinning than did minimum DBP, which had
a greater impact on progressive macular GCIPL thinning
than did minimum SBP. Considering previous studies that
revealed DBP to be primarily linked to tissue perfusion,16–19
our results suggest that macular GCIPL may be more critical
to perfusion deficiency than to peripapillary RNFL. However,
because we found a close correlation between SBP and
DBP measurements, these results could be statistically differ-
ent representations of the fact that systemic hypotension is
associated with structural progression. Further research is
needed to determine whether SBP and DBP differentially
affect peripapillary RNFL and macular GCIPL.
IOP fluctuation is associated with structural progression,
particularly progressive peripapillary RNFL thinning, but
not with progressive macular GCIPL thinning. Mean IOP
and peak IOP were not associated with any kind of struc-
tural progression. Although the relationship between long-
term IOP fluctuation and glaucoma progression remains
controversial,20–24 our results are consistent with those of
the Advanced Glaucoma Intervention Study (AGIS): long-
term IOP fluctuation was the most critical risk factor for VF
progression in glaucoma.22 A univariable analysis performed
by a large retrospective study of patients treated for POAG
or primary angle closure glaucoma demonstrated that peak
IOP and IOP fluctuation were significantly associated with
disease progression; a multivariable analysis conducted by
the same study revealed that only IOP fluctuation was signif-
icantly associated with disease progression.21 A retrospec-
tive chart review found a significant association between
IOP fluctuation and glaucoma progression.23 However, these
results contradict those of the Early Manifest Glaucoma
Trial (EMGT), which observed that the mean IOP—not IOP
fluctuation—was related to disease progression.20 These
divergent results may be ascribed to differences in the
research population; e.g., participants in the EMGT included
untreated patients with early glaucoma.24 By contrast, the
present investigation considered patients who were treated
for diagnosed NTG. The mean IOP in our study was also
lower than that reported by the EMGT (13.1 ± 1.7 vs. 20.7
± 4.1 mm Hg). Above all, our study reflects the clinical situ-
ation in which the patient’s treatment changes with their
IOP—i.e., the subjects in this study were likely to have
received additional medication when the mean IOP was
considered elevated or a high peak IOP was observed. Our
findings do not suggest that the average IOP is unrelated to
structural progression but rather that IOP fluctuations could
also affect glaucoma progression in clinical settings where
treatment is altered to reach a target IOP. Hence, considering
that the mean IOP of our participants was 13.0 mm Hg, our
results recommend the reduction of IOP fluctuations even
in patients with a mean IOP of ≤ 15 mm Hg.
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Our study confirmed disc hemorrhage as a risk factor
for NTG progression.6,25 In agreement with the results of
previous studies,6,26,27 we found the HR of disc hemor-
rhage for structural progression defined as progressive peri-
papillary RNFL or macular GCIPL thinning to be 2.085
(progressive peripapillary RNFL thinning, 2.640; progressive
macular GCIPL thinning, 2.205). While the etiology of disc
hemorrhage is unclear, both mechanical28,29 and vascular
mechanisms30,31 have been hypothesized. Quigley et al.28
suggested that disc hemorrhage occurs due to microvascu-
lar damage during posterior bowing of the lamina cribrosa.
Sharpe et al.32 reported that laminar disinsertions were
more frequently detected in glaucoma patients with disc
hemorrhage. These results suggest that disc hemorrhage
could be closely related to laminar changes in glaucoma
patients. Hence, laminar damage can occur even if the IOP
is well-controlled in patients with normal-tension glaucoma
that might have caused the structural progression. On the
other hand, some studies have reported that systemic vascu-
lar diseases, such as hypertension, diabetes mellitus, and
atherosclerosis, can induce ischemic changes around the
optic disc, increasing the incidence of disc hemorrhage.33–35
Furthermore, primary vascular dysregulation (i.e., Flam-
mer syndrome) might be associated with disc hemorrhage
in glaucoma patients.30 Similar to systemic hypotension,
ischemic changes induced by a disc hemorrhage might
therefore affect the structural progression of NTG eyes.
Previous studies have reported that diabetes contributes
to an increased risk of developing open-angle glaucoma.36–39
These results are supported by evidence implicating
impaired autoregulation in the development of glaucoma—
especially normal-tension glaucoma.40,41 However, few stud-
ies have been published on the relationship between glau-
coma progression and diabetes. In contrast with our own
findings, the Advanced Glaucoma Intervention Study (AGIS)
found no significant difference between progressive VF loss
and diabetes.22 We excluded subjects with MD values of
below −20.0dB, which may have resulted in a limited enroll-
ment of participants with advanced glaucoma. Furthermore,
whereas the AGIS evaluated VF changes, we investigated
structural progression using OCT. Our results suggest that
diabetes-induced glaucoma damage may be more evident
in early glaucoma or may alter structure significantly more
than function. Further study is required to confirm whether
diabetes-induced changes in glaucoma differ according to
the stage of glaucoma and whether such changes differen-
tially affect structure and function.
Although myopia and myopic optic disc changes are
reportedly associated with glaucoma progression,42–44 our
study did not confirm these results. This controversy may be
ascribed to differences between the study populations. Most
studies that found an association between myopic optic disc
changes and glaucoma progression included glaucomatous
eyes with myopia. In contrast, the present study investigated
NTG eyes regardless of myopia. The mean AL of our partici-
pants was 24.35 mm,which is relatively close to emmetropia.
Our results suggest that NTG progression with myopia and
myopic optic disc changes may significantly affect glauco-
matous eyes with myopia but not glaucomatous eyes with
emmetropia or hyperopia.
Univariable Cox regression analysis showed that CCB has
a protective effect against glaucoma progression; because
this association became nonsignificant in the multivariable
Cox regression analysis, our results suggest that the protec-
tive effect of CCB may be related to BP. Prior research
demonstrated the effect of CCB on VF improvements in
NTG.45,46 In particular, one study reported that low doses of
CCB could be used to treat vascular dysregulation in glauco-
matous eyes,47 and another reported that low doses of CCB
could be safer and more efficient than conventional doses
for hypertension management.48 In the present study, no
patients had received low doses of CCB. In addition, previ-
ous studies have reported that CCB has a stronger effect
among younger glaucoma patients with other diseases, such
as Flammer syndrome.49–52 By contrast, another recent study
showed that CCB use increased the risk for development of
POAG.53 These conflicting results may again be attributable
to the heterogeneity of patients with NTG. Hence, although
the effect of CCB may be limited in patients with NTG caused
by reasons such as IOP fluctuation or myopia, CCB may be
beneficial for patients with NTG attributable to the dysregu-
lation of blood vessels.
This study was subject to several limitations. First,
we only investigated structural progression, not functional
progression, and chose the inclusion and exclusion crite-
ria to detect structural progression. VF is generally consid-
ered to be more informative for detecting progression in
moderate to advanced glaucoma,54 while OCT is considered
more sensitive to the detection of progression in the early
stages of the disease.9,55,56 This difference can be partially
ascribed to the difficulty in detecting structural progression
in advanced glaucoma due to the floor effect.55,57 There-
fore eyes with advanced glaucoma were excluded from this
study, and the risk factors and cutoff values identified by our
study may not be applicable to advanced glaucoma. Second,
only daytime IOP and BP were measured. Although recent
studies have reported the influence of nocturnal systemic
hypotension on glaucoma progression,58,59 the retrospective
nature of this study precluded the obtainment of nocturnal
measurements. Nonetheless, our results show that, similar to
nocturnal hypotension or nocturnal drops in BP, minimum
daytime SBP and DBP could be potential risk factors for
glaucoma progression. Third, because of the limited patient
records, antihypertensive medication data were only avail-
able for 34 eyes. The limited data from which our results
were derived may therefore restrict the reproducibility of our
study. Further studies with larger sample sizes are warranted
to confirm this relationship. Fourth, because of the retro-
spective design of our study, the sequential relationship
between BP/IOP variables and structural progression could
not be demonstrated. For example, changes in treatment due
to suspected progression may result in IOP fluctuation. In
this case, IOP fluctuation does not cause structural progres-
sion, but IOP fluctuation may increase due to the change
in treatment. To minimize this possibility, we only analyzed
IOP and BP values measured before structural progression
was detected. Finally, BP was measured in the upper right
arm, and the relationship between BP measured in the arm
and at the retrobulbar remains unclear. Therefore the perfu-
sion pressure calculated in this study should be consid-
ered an approximate value. Future research may benefit
from directly measuring the retrobulbar perfusion pressure
directly or analyzing the degree of perfusion using instru-
ments such as OCT angiography.
In conclusion, disc hemorrhage, diabetes, and systemic
hypotension were associated with structural progression in
medically treated NTG eyes. The tree analysis showed that
SBP could feature a stronger association with progressive
peripapillary RNFL thinning than could DBP and vice versa
for progressive macular GCIPL thinning. We also used tree
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analysis to identify a target BP to prevent structural progres-
sion and expect that these results could help to prevent
structural progression in NTG eyes.
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